BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
45.695 EUR
-0.5 (-1.08%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 53 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. BRM also has an excellent dividend rating. These ratings could make BRM a good candidate for value and dividend investing.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
BRM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BRM has a Return On Assets (6.23%) which is comparable to the rest of the industry.
BRM has a Return On Equity of 32.55%. This is amongst the best in the industry. BRM outperforms 83.02% of its industry peers.
BRM has a Return On Invested Capital of 16.42%. This is in the better half of the industry: BRM outperforms 79.25% of its industry peers.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 13.94%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
With a Profit Margin value of 12.57%, BRM perfoms like the industry average, outperforming 52.83% of the companies in the same industry.
With an excellent Operating Margin value of 33.51%, BRM belongs to the best of the industry, outperforming 84.91% of the companies in the same industry.
BRM's Operating Margin has declined in the last couple of years.
BRM has a Gross Margin of 73.15%. This is in the better half of the industry: BRM outperforms 60.38% of its industry peers.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
Compared to 1 year ago, BRM has less shares outstanding
BRM has less shares outstanding than it did 5 years ago.
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
BRM has an Altman-Z score of 2.23. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM has a Altman-Z score of 2.23. This is comparable to the rest of the industry: BRM outperforms 43.40% of its industry peers.
BRM has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as BRM would need 3.20 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.20, BRM is in the better half of the industry, outperforming 60.38% of the companies in the same industry.
A Debt/Equity ratio of 2.41 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a Debt to Equity ratio of 2.41. This is amonst the worse of the industry: BRM underperforms 81.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
ROIC/WACC1.94
WACC8.45%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.27, BRM is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
BRM has a Quick Ratio of 1.17. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 67.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 460.68% over the past year.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 1.26%.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
The Earnings Per Share is expected to grow by 35.26% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -4.97% on average over the next years.
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BRM is valuated reasonably with a Price/Earnings ratio of 8.16.
Based on the Price/Earnings ratio, BRM is valued cheaper than 90.57% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.22. BRM is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 8.79 indicates a reasonable valuation of BRM.
BRM's Price/Forward Earnings ratio is rather cheap when compared to the industry. BRM is cheaper than 88.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.58, BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.16 | ||
| Fwd PE | 8.79 |
4.2 Price Multiples
88.68% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
100.00% of the companies in the same industry are more expensive than BRM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.13 | ||
| EV/EBITDA | 6.74 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
A more expensive valuation may be justified as BRM's earnings are expected to grow with 73.98% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.22%
EPS Next 3Y73.98%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.92%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.83, BRM pays a better dividend. On top of this BRM pays more dividend than 94.34% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, BRM pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.92% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
82.81% of the earnings are spent on dividend by BRM. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
FRA:BRM (12/18/2025, 5:23:11 PM)
45.695
-0.5 (-1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap93.02B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price Target45.88 (0.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.92% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)0.77%
PT rev (3m)3.21%
EPS NQ rev (1m)-0.47%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)1.22%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)2.19%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)1.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.16 | ||
| Fwd PE | 8.79 | ||
| P/S | 2.27 | ||
| P/FCF | 7.13 | ||
| P/OCF | 6.56 | ||
| P/B | 5.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.74 |
EPS(TTM)5.6
EY12.26%
EPS(NY)5.2
Fwd EY11.38%
FCF(TTM)6.41
FCFY14.03%
OCF(TTM)6.97
OCFY15.24%
SpS20.13
BVpS7.77
TBVpS-9.91
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.23 |
F-Score6
WACC8.45%
ROIC/WACC1.94
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year262.1%
EBIT Next 3Y50.55%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 479.55% in the next year.